AI Article Synopsis
- The text discusses a rare case of an infant suffering from both autoimmune hemolytic anemia (AIHA) and glucose-6-phosphate dehydrogenase (G6PD) deficiency, highlighting the unusual occurrence of these two conditions together, particularly in infants.
- It mentions that the infant also had a urinary tract infection caused by Escherichia coli and had received recent pneumococcal vaccination, linking these factors to the development of the conditions.
- The goal of the study is to analyze possible connections between the conditions, examine the role of the vaccine, and review existing literature on these topics.
Article Abstract
Autoimmune hemolytic anemia (AIHA) and glucose-6-phosphate dehydrogenase (G6PD) deficiency are two distinct causes of hemolysis in children and a combination of both diseases is considered rare, especially in early infancy. We present such a rare case of severe AIHA in an infant with G6PD deficiency in the setting of Escherichia coli urinary tract infection and recent pneumococcal vaccination history, with the goal of analyzing potential links between them, examining the causative role of vaccines, and reviewing available literature.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449400 | PMC |
| http://dx.doi.org/10.7759/cureus.68552 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The medium-fluorescence reticulocyte ratio is an independent predictor of G6PD deficiency neonates.
Int J Hematol
January 2025
Children's Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China.
Objective: G6PD deficiency is a potentially life-threatening condition in neonates presenting with hyperbilirubinemia. This study aims to identify clinical and laboratory predictors of G6PD deficiency in neonates presenting with hyperbilirubinemia.
Methods: This was a retrospective study of 227 term neonates admitted to Heyuan People's Hospital from January 2019 to October 2023.
Quantifying Plasmodium vivax radical cure efficacy: a modelling study integrating clinical trial data and transmission dynamics.
Lancet Infect Dis
January 2025
Institut Pasteur, Université Paris Cité, G5 Épidémiologie et Analyse des Maladies Infectieuses, Paris, France. Electronic address:
Background: Plasmodium vivax forms dormant liver stages (hypnozoites) that can reactivate weeks to months after primary infection. Radical cure requires a combination of antimalarial drugs to kill both the blood-stage and liver-stage parasites. Hypnozoiticidal efficacy of the liver-stage drugs primaquine and tafenoquine cannot be estimated directly because hypnozoites are undetectable.
View Article and Find Full Text PDFSocial Media Content Analysis of Public and Private Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency Facebook Groups.
Acta Med Philipp
December 2024
Institute of Human Genetics, National Institutes of Health, University of the Philippines Manila.
Background: As social media continue to grow as popular and convenient tools for acquiring and disseminating health information, the need to investigate its utilization by laypersons encountering common medical issues becomes increasingly essential.
Objectives: This study aimed to analyze the content posted in Facebook groups for Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency and how these engage the members of the group.
Methods: This study employed an inductive content analysis of user-posted content in both public and private Facebook groups catering specifically to G6PD deficiency.
Safety and efficacy of three alternative regimens against relapsing Plasmodium vivax malaria in glucose 6-phosphate dehydrogenase deficient patients in the Brazilian Amazon (ALTPRIM).
Clin Infect Dis
January 2025
Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil.
Background: Daily primaquine-induced hemolysis is a common cause of complications during Plasmodium vivax malaria treatment in individuals with glucose 6-phosphate dehydrogenase deficiency (G6PDd). Alternative regimens balancing safety and efficacy are needed.
Methods: G6PDd participants with P.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!